TNSN88004A1 - Antigenes de surface du virus de l'hepatite b et antigenes hybrides les contenant - Google Patents
Antigenes de surface du virus de l'hepatite b et antigenes hybrides les contenantInfo
- Publication number
- TNSN88004A1 TNSN88004A1 TNTNSN88004A TNSN88004A TNSN88004A1 TN SN88004 A1 TNSN88004 A1 TN SN88004A1 TN TNSN88004 A TNTNSN88004 A TN TNSN88004A TN SN88004 A TNSN88004 A TN SN88004A TN SN88004 A1 TNSN88004 A1 TN SN88004A1
- Authority
- TN
- Tunisia
- Prior art keywords
- antigens
- hepatitis
- hybrid
- virus surface
- surface antigens
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 6
- 108091007433 antigens Proteins 0.000 title abstract 6
- 102000036639 antigens Human genes 0.000 title abstract 6
- 241000700721 Hepatitis B virus Species 0.000 title abstract 2
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
CETTE INVENTION CONCERNE DES ANTIGENES DE SURFACE DU VIRUS DE L'HEPATITE B ET ANTIGENES HYDRIDES LES CONTENANT AINSI QUE LE CLONAGE DE GENES QUI CODENT POUR CES ANTIGENES DANS DES LEVURES, PAR L'USAGE DE TECHNIQUE D'ADN RECOMBINANT. LES ANTIGENES DE L'INVENTION SONTUTILISABLES POUR LA PREPARATION DE VACCIN, NOTAMMENT CONTRE L'HEPATITE B OU CONTRE LA MALARIA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US932587A | 1987-01-30 | 1987-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN88004A1 true TNSN88004A1 (fr) | 1990-07-10 |
Family
ID=21736956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNTNSN88004A TNSN88004A1 (fr) | 1987-01-30 | 1988-02-03 | Antigenes de surface du virus de l'hepatite b et antigenes hybrides les contenant |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0278940A3 (fr) |
JP (1) | JPS6463382A (fr) |
KR (1) | KR880009130A (fr) |
CN (1) | CN1031395A (fr) |
AP (1) | AP56A (fr) |
AU (1) | AU1093088A (fr) |
DD (3) | DD285994A5 (fr) |
DK (1) | DK43188A (fr) |
FI (1) | FI880428A (fr) |
HU (1) | HUT50876A (fr) |
IL (1) | IL85216A0 (fr) |
MA (1) | MA21169A1 (fr) |
NO (1) | NO880395L (fr) |
NZ (1) | NZ223297A (fr) |
OA (1) | OA08801A (fr) |
PT (1) | PT86640B (fr) |
SU (1) | SU1746887A3 (fr) |
TN (1) | TNSN88004A1 (fr) |
YU (1) | YU17488A (fr) |
ZA (1) | ZA88488B (fr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10299017I2 (de) | 1987-06-22 | 2005-05-25 | Medeva Holdings Bv | Hepatitis-B-Oberfl{chenantigen enthaltendes Peptid. |
IL89991A0 (en) * | 1988-04-25 | 1989-12-15 | Phillips Petroleum Co | Expression of hepatitis b pres2 protein in methylotrophic yeasts |
EP0345792A3 (fr) * | 1988-06-10 | 1991-05-02 | F. Hoffmann-La Roche Ag | Protéines fusionnées HTLV-I/HIV-I |
FR2635532B1 (fr) * | 1988-07-29 | 1992-05-22 | Pasteur Institut | Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant |
US5130247A (en) * | 1989-09-19 | 1992-07-14 | Merck & Co., Inc. | Expression of fusion protein of HIV envelope and HBsAG |
US5130248A (en) * | 1989-09-19 | 1992-07-14 | Merck & Co., Inc. | Expression of fusion protein of HIV envelope and HBsAg |
CA2025481A1 (fr) * | 1989-09-19 | 1991-03-20 | Peter J. Kniskern | Vaccin contre le sida et l'hepatite b |
EP0491077A1 (fr) * | 1990-12-19 | 1992-06-24 | Medeva Holdings B.V. | Composition utilisée comme agent thérapeutique contre des maladies hépatiques chroniques |
DK0614465T3 (da) * | 1991-11-16 | 1999-09-27 | Smithkline Beecham Biolog | Hybridprotein mellem CS fra Plasmodium og HBsAg |
ATE199158T1 (de) * | 1991-12-23 | 2001-02-15 | Bayer Ag | Hbv amplifizierungssonden zur verwendung in hybridisierungssandwichassay in der lösungsphase |
US6297048B1 (en) | 1992-02-04 | 2001-10-02 | Chiron Corporation | Hepatitis therapeutics |
US6169171B1 (en) | 1992-02-27 | 2001-01-02 | Smithkline Beecham Biologicals (S.A.) | Hybrid protein between CS from plasmodium and HBSAG |
US5928902A (en) * | 1992-02-27 | 1999-07-27 | Smithkline Beecham Biologicals (S.A.) | Hybrid protein between CS from plasmodium and HBsAg |
US6667387B1 (en) | 1996-09-30 | 2003-12-23 | N.V. Innogenetics S.A. | HCV core peptides |
US6709828B1 (en) | 1992-03-06 | 2004-03-23 | N.V. Innogenetics S.A. | Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them |
BR9305435A (pt) * | 1992-03-06 | 1994-12-27 | Innogenetics Nv | Processo para determinação de peptídeos correspondendo a epítopos imunologicamente importantes e seu uso em um processo para determinação de anticorpos ou peptídeos biotinilados correspondendo a epítopos imunologicamente importantes, processo para preparação dos mesmos e composições contendo os mesmos |
EP0565794A1 (fr) * | 1992-04-14 | 1993-10-20 | British Biotech Pharmaceuticals Limited | Induction des réponses CTL |
EP0835663B1 (fr) | 1992-05-23 | 2009-09-30 | GlaxoSmithKline Biologicals S.A. | Vaccins combinés contenant des antigènes de surface du virus de l'Hépatite B et d'autres antigènes |
CN1063343C (zh) * | 1993-04-27 | 2001-03-21 | 中国科学院上海生物化学研究所 | 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白 |
US6235888B1 (en) | 1994-10-05 | 2001-05-22 | The General Hospital Corporation | Hepatitis C virus vaccine |
RU2189254C2 (ru) * | 1995-06-06 | 2002-09-20 | Америкэн Хоум Продактс Корпорэйшн | Вакцины против вирусов гепатита |
ATE386811T1 (de) | 1996-04-05 | 2008-03-15 | Novartis Vaccines & Diagnostic | Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen |
WO1998012332A1 (fr) | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions et procedes de traitement de maladies intracellulaires |
GB9623233D0 (en) | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
DE69935606T9 (de) | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
UA79735C2 (uk) | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах |
CN100381171C (zh) * | 2004-12-30 | 2008-04-16 | 成都生物制品研究所 | 含前s1、前s2和s抗原决定簇的乙肝表面抗原复合颗粒 |
CN102675430B (zh) * | 2005-08-12 | 2014-08-27 | 上海贺普药业股份有限公司 | 乙型肝炎病毒表面l蛋白相关肽 |
EP2397856B1 (fr) | 2006-03-14 | 2013-11-13 | Oregon Health and Science University | Procédés pour détecter une infection de tuberculose à mycobactérie |
AU2007293673B2 (en) | 2006-09-07 | 2013-06-27 | Glaxosmithkline Biologicals S.A. | Vaccine |
KR100836745B1 (ko) * | 2007-01-31 | 2008-06-10 | (주)두비엘 | Hbv 백신 및 그의 제조 방법 |
US8188214B2 (en) | 2007-02-28 | 2012-05-29 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
EP2142211A1 (fr) | 2007-05-02 | 2010-01-13 | GlaxoSmithKline Biologicals S.A. | Vaccin |
US9415006B2 (en) | 2008-05-23 | 2016-08-16 | The Regents Of The University Of Michigan | Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same |
WO2010099472A2 (fr) | 2009-02-27 | 2010-09-02 | The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services | Polypeptides spanx-b et leur utilisation |
GB201105981D0 (en) | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
ES2752190T3 (es) | 2012-09-14 | 2020-04-03 | Us Health | Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso |
CN108289940B (zh) | 2015-08-03 | 2023-01-13 | 美国卫生和人力服务部 | Brachyury缺失突变体、编码brachyury缺失突变体的非酵母载体及其用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2145092B (en) * | 1983-01-28 | 1988-04-07 | Univ New York | Protective peptide antigen |
AU584580B2 (en) * | 1982-09-08 | 1989-06-01 | Smith Kline - Rit | Hepatitis B virus vaccine |
ATE73349T1 (de) * | 1984-06-18 | 1992-03-15 | Chiron Corp | Hepatitisoberflaechenantigenpartikelvakzin. |
EP0171908A3 (fr) * | 1984-07-11 | 1987-07-15 | Takeda Chemical Industries, Ltd. | Antigène de surface du virus de l'hépatite B et production |
GB8421282D0 (en) * | 1984-08-22 | 1984-09-26 | Connaught Lab | Multispecific antigenic proteins |
ATE70308T1 (de) * | 1984-09-12 | 1991-12-15 | Chiron Corp | Hybridpartikel-immunogene. |
EP0180012A1 (fr) * | 1984-10-27 | 1986-05-07 | Wolfram H. Prof. Dr. Gerlich | Séquence de polypeptide immunogène du virus de l'hépatite B |
CN86100979A (zh) * | 1985-02-07 | 1986-12-17 | 史密丝克莱恩贝克曼公司 | 疟疾疫苗的制备方法 |
US4774175A (en) * | 1985-03-01 | 1988-09-27 | Centocor, Inc. | Immunochemical methods for the detection of antibody against HTLV-III |
US4683294A (en) * | 1985-04-03 | 1987-07-28 | Smith Kline Rit, S.A. | Process for the extraction and purification of proteins from culture media producing them |
EP0225887B1 (fr) * | 1985-04-08 | 1994-06-08 | Amgen Inc. | Procede et activeur hybride permettant de commander la transcription de genes exogenes |
FR2581394B1 (fr) * | 1985-05-02 | 1988-08-05 | Grp Genie Genetique | Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes |
US4816564A (en) * | 1986-01-31 | 1989-03-28 | Merck & Co., Inc. | Method for producing hepatitis B virus proteins in yeast |
CA1310602C (fr) * | 1986-06-03 | 1992-11-24 | Hajime Horii | Promoteur de la levure et procede pour la preparation de proteines heterologues |
-
1988
- 1988-01-25 EP EP88870008A patent/EP0278940A3/fr not_active Withdrawn
- 1988-01-25 ZA ZA88488A patent/ZA88488B/xx unknown
- 1988-01-25 AP APAP/P/1988/000078A patent/AP56A/en active
- 1988-01-26 NZ NZ223297A patent/NZ223297A/en unknown
- 1988-01-26 IL IL85216A patent/IL85216A0/xx unknown
- 1988-01-26 SU SU884355055A patent/SU1746887A3/ru active
- 1988-01-27 OA OA59269A patent/OA08801A/fr unknown
- 1988-01-27 PT PT86640A patent/PT86640B/pt not_active IP Right Cessation
- 1988-01-28 AU AU10930/88A patent/AU1093088A/en not_active Abandoned
- 1988-01-28 DK DK043188A patent/DK43188A/da not_active Application Discontinuation
- 1988-01-29 DD DD88334295A patent/DD285994A5/de not_active IP Right Cessation
- 1988-01-29 JP JP63021137A patent/JPS6463382A/ja active Pending
- 1988-01-29 YU YU00174/88A patent/YU17488A/xx unknown
- 1988-01-29 FI FI880428A patent/FI880428A/fi not_active IP Right Cessation
- 1988-01-29 MA MA21406A patent/MA21169A1/fr unknown
- 1988-01-29 HU HU88409A patent/HUT50876A/hu unknown
- 1988-01-29 DD DD88334296A patent/DD285612A5/de unknown
- 1988-01-29 NO NO880395A patent/NO880395L/no unknown
- 1988-01-29 DD DD88334294A patent/DD284899A5/de not_active IP Right Cessation
- 1988-01-30 CN CN88100483A patent/CN1031395A/zh active Pending
- 1988-01-30 KR KR1019880000825A patent/KR880009130A/ko not_active Application Discontinuation
- 1988-02-03 TN TNTNSN88004A patent/TNSN88004A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
DD284899A5 (de) | 1990-11-28 |
DK43188A (da) | 1988-07-31 |
MA21169A1 (fr) | 1988-10-01 |
PT86640B (pt) | 1992-01-31 |
NO880395L (no) | 1988-08-01 |
YU17488A (en) | 1991-02-28 |
AP8800078A0 (en) | 1987-11-01 |
FI880428A (fi) | 1988-09-13 |
OA08801A (fr) | 1989-03-31 |
AU1093088A (en) | 1988-08-04 |
DD285612A5 (de) | 1990-12-19 |
EP0278940A2 (fr) | 1988-08-17 |
IL85216A0 (en) | 1988-07-31 |
JPS6463382A (en) | 1989-03-09 |
SU1746887A3 (ru) | 1992-07-07 |
CN1031395A (zh) | 1989-03-01 |
KR880009130A (ko) | 1988-09-14 |
FI880428A0 (fi) | 1988-01-29 |
NZ223297A (en) | 1991-06-25 |
AP56A (en) | 1989-09-26 |
DK43188D0 (da) | 1988-01-28 |
NO880395D0 (no) | 1988-01-29 |
HUT50876A (en) | 1990-03-28 |
PT86640A (pt) | 1988-02-01 |
EP0278940A3 (fr) | 1988-12-07 |
DD285994A5 (de) | 1991-01-10 |
ZA88488B (en) | 1988-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN88004A1 (fr) | Antigenes de surface du virus de l'hepatite b et antigenes hybrides les contenant | |
DE69233186D1 (de) | Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung | |
CO5070644A1 (es) | Vacunas que comprenden proteinas e6 de hpv y/o e7 de hpv junto con un oligonucleotido cpg como adyudante | |
EE05138B1 (et) | Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin | |
DK0835133T3 (da) | Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf | |
ZA987591B (en) | Vaccine. | |
CA2102918A1 (fr) | Vaccin genetique anti-virus de l'immunodeficience | |
GEP19981289B (en) | Method for Preparing Preserved Medicinal Means Containing Human Protein and Medicinal Means | |
ES2156852T3 (es) | Citoquina mamifera, il-11. | |
DE69332831D1 (de) | Rekombinanter schweinepocken-virus | |
EP0429477A4 (en) | Synthetic vaccine against aids virus | |
AU3904685A (en) | Cloning of dna for protozoal antigens | |
EP0090581A3 (fr) | Petits peptides specifiques des antigènes de la fièvre aphteuse | |
DE3666529D1 (en) | Canine parvovirus vaccines | |
EP0342860A3 (fr) | Nouvelle protéine, séquences contenant le gène de cette protéine, vecteurs, procédés de préparation et utilisation | |
ZA853081B (en) | Vaccine against rabies and process for preparation thereof | |
PT84640A (fr) | Vecteur viral contenant un gene codant pour une glycoproteine (gp) de l:enveloppe du virus responsable du s.i.d.a. et anticorps contre les dits glycoproteines | |
FR2693472B1 (fr) | Mutants du virus de la rhinotrachéite infectieuse bovine, délétés dans l'un des gènes des glycoprotéines mineures, vaccins préparés à partir de ces souches, méthodes de production et méthodes d'utilisation. | |
FR2635532B1 (fr) | Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant | |
FR2600079B1 (fr) | Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus | |
IL86675A (en) | Immunogen containing non- infectious hiv particles and pharmaceutical compositions containing the same | |
EP1073461A4 (fr) | Chimeres virales comprenant des elements genetiques de caev et de vih-1 | |
FR2617715B1 (fr) | Vecteur viral et adn recombinant codant pour une ou des proteines de surface (ha et/ou f) d'un morbillivirus, culture cellulaire infectee, proteines obtenues, vaccin et anticorps obtenus | |
HUP0003511A2 (hu) | Hepatitisz-B-vírus polipeptidek | |
EP0309898A3 (fr) | Méthode pour l'induction d'une réponse de cellule T cytotoxique |